Drugmaker Gilead
-
{
- All
- News
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Ties Up With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Incsaid on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
-
Gilead Says In Talks With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
-
US Drugmaker To Donate 400,000 Covid Treatment Tablets To India
Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to India as the country fights a raging pandemic that has morgues and hospitals overflowing.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Ties Up With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Incsaid on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
-
Gilead Says In Talks With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
-
Report: US Drug Maker Was Focused on Profits, Not Patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, US Senate investigators said Tuesday.
